BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 28589214)

  • 1. [Individualized treatment strategies for Clostridium difficile infections].
    Solbach P; Dersch P; Bachmann O
    Internist (Berl); 2017 Jul; 58(7):675-681. PubMed ID: 28589214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and management of Clostridium difficile infection.
    Dupont HL
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?
    Manthey CF; Eckmann L; Fuhrmann V
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1239-1250. PubMed ID: 28766951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.
    Mizusawa M; Doron S; Gorbach S
    Drugs Aging; 2015 Aug; 32(8):639-47. PubMed ID: 26233437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best strategies in recurrent or persistent Clostridium difficile infection.
    Cocanour CS
    Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile colitis: review of the therapeutic approach.
    Joseph J; Singhal S; Patel GM; Anand S
    Am J Ther; 2014; 21(5):385-94. PubMed ID: 22990077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Clostridium difficile infections.
    Soriano MM; Johnson S
    Infect Dis Clin North Am; 2015 Mar; 29(1):93-108. PubMed ID: 25573676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate.
    Fischer M; Sipe BW; Rogers NA; Cook GK; Robb BW; Vuppalanchi R; Rex DK
    Aliment Pharmacol Ther; 2015 Aug; 42(4):470-6. PubMed ID: 26096320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and opportunities in the management of Clostridium difficile infection.
    DuPont HL
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):863-74. PubMed ID: 25012255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
    Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
    Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clostridium difficile infecion--diagnostics, prevention and treatment].
    Piekarska M; Wandałowicz AD; Miigoć H
    Pol Merkur Lekarski; 2014 Apr; 36(214):278-82. PubMed ID: 24868904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
    Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
    Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.